Payment overview · 2025
General Payments
$3,672.01
100 reported records · 22 companies
Healthcare provider profile · identity verified
Sabrina Arsala
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FRESNO, CA · NPI 1558119305
Verified facts
What the public records show
CMS Open Payments records show Sabrina Arsala received $3,672.01 in general payments during 2025 across 100 reported records.
Gilead Sciences, Inc. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $672.94 | 18.3% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $492.88 | 13.4% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $391.34 | 10.7% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $334.33 | 9.1% | 16 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $278.46 | 7.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $226.97 | 6.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $182.19 | 5.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $177.23 | 4.8% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $171.52 | 4.7% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $146.54 | 4.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 3.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $109.02 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.12 | 2.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.93 | 1.7% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $55.84 | 1.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.48 | 1.1% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $35.64 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.37 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.00 | 0.6% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $18.52 | 0.5% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $16.91 | 0.5% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $13.78 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,660.45 | 99 |
| Education | $11.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $492.88 | 12 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $353.51 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $274.59 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $182.19 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $181.96 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $181.05 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $171.52 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $168.61 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $164.25 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $158.62 | 11 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $120.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $119.74 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $109.85 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $109.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $100.65 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $91.72 | 6 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $75.12 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.25 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.25 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $59.88 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $55.84 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $55.84 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $55.84 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $55.84 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $45.92 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.22 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $35.64 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.68 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $27.29 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.33 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,672.01 · 100 records | Gilead Sciences, Inc. | AIRSUPRA, APTIMA, AREXVY, Auvelity, BEYFORTUS, BREZTRI, COMIRNATY, Descovy, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GEMTESA, INCEPTIV, INTELLIS ADAPTIVESTIM, ImmunoCAP, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NUCALA, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SMARTVEST, SPRAVATO, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, Yeztugo, ZAVZPRET, ZENPEP, ZORYVE | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error